Literature DB >> 10456294

Intra-individual variability and influence of urine collection period on dextromethorphan metabolic ratios in healthy subjects.

J Chládek1, G Zimová, J Martínková, I Tůma.   

Abstract

The aim of the study was to evaluate intra-individual variability in metabolic ratios (MRs) of dextromethorphan (DM) in healthy volunteers and to compare the MRs in urine collected 0-4, 0-8 and 0-24 h post-dose. Urinary molar ratios of DM to dextrorphan (MR1) and of DM to methoxymorphinan (MR2) were obtained after a single oral 27.5 mg dose of DM hydrobromide to ten healthy male and four female Caucasians (ten extensive metabolizers (EM) and four poor metabolizers (PM) of DM) to probe activities of CYP2D6 and CYP3A, respectively. Seven EM and one PM received DM on three additional occasions within 2 months. For the seven EM, the intra-individual variability (CVw) in the MRs obtained in the three urine collections ranged from 11 to 93% (MR1) and from 8 to 77% (MR2). The mean CVw estimated separately for the 4, 8 and 24 h urines by two-way analysis of variance reached 58, 57 and 44% for the MR1 and 50, 42 and 31% for the MR2, respectively. For all 14 subjects, the log-transformed ratios (MR1) obtained in the 24 h urines were highly correlated with those in either the 8 h (rs = 0.967, P < 0.0001) or 4 h urines (rs = 0.946, P < 0.0001). Correlation between the log-transformed MR2s were weaker (24 h vs. 8 h: rs = 0.829, P < 0.0001, 24 h vs. 4 h: rs = 0.831, P < 0.0001). The MR1s in 4 h and 8 h urines were only 2 and 9% less than those in 24 h urines (median differences) and varied from 48 and 47% below to 85 and 55% above (95% -CI for the differences). However, the MR2s in the 4 h and 8 h urines were shifted towards higher values by 49 and 23% and the corresponding 95% -CI limits were: 16-164% (4 h vs. 24 h) and 30-119% (8 h vs. 24 h). In conclusion, MR1 values in the 4 h urine collection agree well with those in longer collections and their use in epidemiological studies can be recommended. The intra-individual variability of approximately 50% in the MR1 has to be taken into account in clinical studies with within-subject design. Accurate determination of the MR2 requires at least a 24 h period of urine collection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10456294     DOI: 10.1111/j.1472-8206.1999.tb00011.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  7 in total

Review 1.  Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping.

Authors:  D Frank; U Jaehde; U Fuhr
Journal:  Eur J Clin Pharmacol       Date:  2007-02-02       Impact factor: 2.953

2.  Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Authors:  Waheed Adeola Adedeji; Sharon Iyobor Igbinoba; Titilayo O Fakeye; Ibrahim Adebayo Oladosu; Fatai Adewale Fehintola; Qing Ma; Gene D Morse
Journal:  Expert Rev Clin Pharmacol       Date:  2017-08-30       Impact factor: 5.045

Review 3.  Identifying genomic and developmental causes of adverse drug reactions in children.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-11       Impact factor: 2.533

4.  The effect of grape seed extract on the pharmacokinetics of dextromethorphan in healthy volunteers.

Authors:  Andrew K L Goey; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Eur J Clin Pharmacol       Date:  2013-07-24       Impact factor: 2.953

5.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

6.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects.

Authors:  Christian Funck-Brentano; Pierre-Yves Boëlle; Céline Verstuyft; Célia Bornert; Laurent Becquemont; Jean-Marie Poirier
Journal:  Eur J Clin Pharmacol       Date:  2005-11-17       Impact factor: 2.953

7.  The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity.

Authors:  Jean C Dinh; Erin C Boone; Vincent S Staggs; Robin E Pearce; Wendy Y Wang; Roger Gaedigk; James Steven Leeder; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2021-11-30       Impact factor: 6.875

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.